{"name":"Center for Neurologic Study, La Jolla, California,","slug":"center-for-neurologic-study-la-jolla-california","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Nuedexta","genericName":"Nuedexta","slug":"nuedexta","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Nuedexta","genericName":"Nuedexta","slug":"nuedexta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA0ZkY0RkFkOFYzaERIV0lIY05ITTFFdENjQXNJTXAteDI2LV82UGZtZ1dmamNCcVhoRzQydEZfVVRPanRsZUNRbkJfQ0RCOFMxVlc4eTVXeDNPbUNZYzEw?oc=5","date":"2025-07-01","type":"trial","source":"nature.com","summary":"Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials - nature.com","headline":"Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBqbFdHWVQ3bGJMTnN0cXVvM1hVX0xmMGExNWw0U0xlZ3o3X3oxU1QwTzN6YWNGZGdPWW9MMUN5U1hfV0pHc3Bidi1CRFBrR19TWWxXVklKRWJfQm0zLWVV?oc=5","date":"2025-06-16","type":"pipeline","source":"nature.com","summary":"Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab | npj Digital Medicine - nature.com","headline":"Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPWmVmMW9taVV1OFM3cUowQmN0eGV5TVNMaDNSUWNMUXlKejRZRm1aRjJaeENENFV5NVJqNmZOclVHUjN5dFRDN3A5d0RITTZLaE12MFNieWkzczR0a2RjSGhiNW1NcDIyMzJxcXBnX1N6TFcwdEhEV2g0VXFNY0J6RzM0RnhLel9MTEtvODhLS2t1b1BDWkRndTZlZDBhM0pNUDR3Q2Fpb3ZRYmZwMG14NkVGclRXaTg?oc=5","date":"2023-05-06","type":"regulatory","source":"San Diego Union-Tribune","summary":"La Jolla scientists help develop drug approved to treat genetic ALS - San Diego Union-Tribune","headline":"La Jolla scientists help develop drug approved to treat genetic ALS - San Diego Union","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBHeXBURHNxck5YQ1B1a2JFS1RXLTNoVDF4UlFQX1B6MU5NWThDQ0FSejNiUmxSYWhiRjFJb2w0eGxiTVp3dWJyQXlIdFVrUUVjd3lBY2VQdC1Hc2xKUmlr?oc=5","date":"2021-03-01","type":"trial","source":"nature.com","summary":"The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism - nature.com","headline":"The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQaUZibW9DenpSTWtWbEl5em14TG1zSEJxeGJrWjg0LTR3QUJjbHpObkJ1dExjUDZfcE9FaVZ0Vl96R2dsVm9HRktVa2h6VmJSSWpSZmZGbGlMVmpqVGl2TUZILTVYRkwxTEZIMU82d2ZTTm9TVXNxaDVCZVVfTlVhVWZ2VExfc1U4ODkyMVowVTR5V1FtVVhmbVNLaENBMEJkWHVfOVl5ZjV4VVF2dS1kTktsek4?oc=5","date":"2017-12-03","type":"pipeline","source":"The UCSD Guardian","summary":"UCSD Researcher Works on DNA Drug to Treat Huntington’s, ALS with Local Company - The UCSD Guardian","headline":"UCSD Researcher Works on DNA Drug to Treat Huntington’s, ALS with Local Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBDOGtHc3RBX0hGdlNXLWFkbjNxeHd4cWhweHNza3Zub1Q0XzNoTWNQYzVWc2FxM2hWQm85NkhwalNXV2hlWVlxMFhLRGFfckVfMmc?oc=5","date":"2017-10-19","type":"pipeline","source":"nature.com","summary":"Research round-up - nature.com","headline":"Research round-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNQmJLNER5TXEwMFRzWlVuMWdvNHgtZXhOWEhmOFVZTnNvTVM1b3UtOXZIVFptcTgzVDlqS3cxM0FvNUxVUTZTM19IV1h4SGlFZEowU1NZS004aW5sSWFlRUJPNHpCVWgzd0VybVV2Wjk1WThabUoycmpkaG1PdGlrTzRHZjlETEpfZVNleHdmRWllZ0RzNHo5LS1ULTU2WlhLRFUtVWZvSWs1RU9Ob3c?oc=5","date":"2017-02-10","type":"trial","source":"The ALS Association","summary":"Nuedexta Trial Demonstrates Promising Results Impacting Bulbar Function in ALS Patients - The ALS Association","headline":"Nuedexta Trial Demonstrates Promising Results Impacting Bulbar Function in ALS Patients","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}